Cyclacel Pharmaceuticals, Inc. (CYCC)
Largest Insider Buys in Sector
CYCC Stock Price History Chart
CYCC Stock Performance
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced …
Insider Activity of Cyclacel Pharmaceuticals, Inc.
Over the last 12 months, insiders at Cyclacel Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Cyclacel Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Cyclacel Pharmaceuticals, Inc. have bought $26,374 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,070 shares for transaction amount of $20,122 was made by Rombotis Spiro George (President and CEO) on 2023‑12‑21.
List of Insider Buy and Sell Transactions, Cyclacel Pharmaceuticals, Inc.
| 2023-12-21 | President and CEO | 6,070 0.6595% | $3.31 | $20,122 | -48.19% | |||
| 2023-12-21 | See Remarks | 1,886 0.2049% | $3.31 | $6,252 | -48.19% | |||
| 2017-02-23 | 10 percent owner | 134,200 3.3648% | $4.34 | $582,079 | -53.33% | |||
| 2014-11-20 | director | 3,100 0.0137% | $3.00 | $9,300 | -75.93% | |||
| 2013-05-21 | President and CEO | 200,000 1.4075% | $3.00 | $600,000 | +16.94% | |||
| 2013-05-21 | See Remarks | 12,948 0.092% | $3.03 | $39,213 | +16.94% | |||
| 2013-05-21 | director | 33,333 0.2346% | $3.00 | $99,999 | +16.94% | |||
| 2011-12-23 | President and CEO | 15,902 0.0288% | $0.49 | $7,871 | +16.00% | |||
| 2011-09-23 | Sale | 10 percent owner | 650,000 1.2397% | $0.51 | $332,930 | +11.43% | ||
| 2011-09-23 | President and CEO | 24,100 0.0453% | $0.51 | $12,171 | +11.43% | |||
| 2011-09-23 | See Remarks | 12,000 0.0223% | $0.50 | $6,000 | +11.43% | |||
| 2011-09-22 | Sale | 10 percent owner | 500,000 1.0235% | $0.60 | $302,350 | +0.65% | ||
| 2011-09-22 | President and CEO | 5,000 0.01% | $0.59 | $2,965 | +0.65% | |||
| 2011-09-13 | President and CEO | 12,400 – | $0.75 | $9,343 | -23.61% | |||
| 2011-08-22 | President and CEO | 9,232 0.0171% | $0.73 | $6,721 | -21.92% | |||
| 2011-05-13 | Sale | 10 percent owner | 150,000 0.3324% | $1.75 | $263,200 | -61.18% | ||
| 2010-11-30 | Sale | 10 percent owner | 142,000 0.3167% | $1.90 | $269,871 | -29.51% | ||
| 2010-11-26 | Sale | 10 percent owner | 58,000 0.1253% | $1.90 | $110,310 | -31.75% | ||
| 2010-10-08 | Sale | 10 percent owner | 183,982 0.3957% | $1.67 | $307,728 | -17.07% | ||
| 2010-05-04 | Sale | VP, Marketing & Sales | 10,000 0.0049% | $0.44 | $4,400 | -36.59% |